EP2242748A1 - Composés thérapeutiques disulfure pour traiter la douleur et les diabètes - Google Patents

Composés thérapeutiques disulfure pour traiter la douleur et les diabètes

Info

Publication number
EP2242748A1
EP2242748A1 EP09701462A EP09701462A EP2242748A1 EP 2242748 A1 EP2242748 A1 EP 2242748A1 EP 09701462 A EP09701462 A EP 09701462A EP 09701462 A EP09701462 A EP 09701462A EP 2242748 A1 EP2242748 A1 EP 2242748A1
Authority
EP
European Patent Office
Prior art keywords
pain
compound
diabetes
mammal
therapeutic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP09701462A
Other languages
German (de)
English (en)
Inventor
Gyorgy F. Ambrus
Mark P. Rubino
Todd M. Heidelbaugh
Phong X. Nguyen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Inc
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of EP2242748A1 publication Critical patent/EP2242748A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/84—Sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Definitions

  • These compounds may be administered to a mammal to treat pain, including visceral pain, pain caused by irritable bowel syndrome, neuropathic pain, and pain caused by dyspepsia.
  • These compounds may be administered to a mammal to treat symptoms of diabetes, including hyperglycemia, hyperlipidemia, decreased levels of blood insulin, and hypertriglyceridemia.
  • a dosage form such as pill, tablet, or capsule for oral administration, or a liquid for injection, is prepared containing the compound, and the dosage form is administered to a mammal needing the treatment.
  • a dosage form such as pill, tablet, or capsule for oral administration, or a liquid for injection
  • a dosage form is prepared containing the compound, and the dosage form is administered to a mammal needing the treatment.
  • suitable dosage forms are known in the art.
  • U.S. Patent No. 7,141,597 describes suitable methods.
  • the dose may vary depending upon the mammal being dosed and the particular condition being treated. A person of ordinary skill in the art can determine the dose appropriate for the situation. For example, for humans, a dose of from about 10 to about 100 mg, given twice a day is contemplated.
  • “treat,” “treating,” or “treatment” refers to the diagnosis, cure, mitigation, treatment, or prevention of disease or other undesirable condition.
  • reference to a compound should be construed broadly to include compounds, pharmaceutically acceptable salts, prodrugs, tautomers, alternate solid forms, non-covalent complexes, and combinations thereof, of a chemical entity of a depicted structural formula or chemical name.
  • a pharmaceutically acceptable salt is any salt of the parent compound that is suitable for administration to an animal or human.
  • a pharmaceutically acceptable salt also refers to any salt which may form in vivo as a result of administration of an acid, another salt, or a prodrug which is converted into an acid or salt.
  • a salt comprises one or more ionic forms of the compound, such as a conjugate acid or base, associated with one or more corresponding counter-ions.
  • Salts can form from or incorporate one or more deprotonated acidic groups (e.g. carboxylic acids), one or more protonated basic groups (e.g. amines), or both (e.g. zwitterions).
  • a prodrug is a compound which is converted to a therapeutically active compound after administration. For example, conversion may occur by hydrolysis of an ester group or some other biologically labile group. Prodrug preparation is well known in the art. For example, “Prodrugs and Drug Delivery Systems,” which is a chapter in Richard
  • [ll]Tautomers are isomers that are in rapid equilibrium with one another.
  • tautomers may be related by transfer of a proton, hydrogen atom, or hydride ion.
  • Alternate solid forms are different solid forms than those that may result from practicing the procedures described herein.
  • alternate solid forms may be polymorphs, different kinds of amorphous solid forms, glasses, and the like.
  • Non-covalent complexes are complexes that may form between the compound and one or more additional chemical species that do not involve a covalent bonding interaction between the compound and the additional chemical species. They may or may not have a specific ratio between the compound and the additional chemical species.
  • Examples might include solvates, hydrates, charge transfer complexes, and the like.
  • One embodiment is a compound represented by the structure:

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne des composés représentés par la formule. Des procédés thérapeutiques, des compositions et des médicaments qui leur sont liés sont également révélés.
EP09701462A 2008-01-11 2009-01-09 Composés thérapeutiques disulfure pour traiter la douleur et les diabètes Withdrawn EP2242748A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2045808P 2008-01-11 2008-01-11
PCT/US2009/030594 WO2009089448A1 (fr) 2008-01-11 2009-01-09 Composés thérapeutiques disulfure pour traiter la douleur et les diabètes

Publications (1)

Publication Number Publication Date
EP2242748A1 true EP2242748A1 (fr) 2010-10-27

Family

ID=40395099

Family Applications (1)

Application Number Title Priority Date Filing Date
EP09701462A Withdrawn EP2242748A1 (fr) 2008-01-11 2009-01-09 Composés thérapeutiques disulfure pour traiter la douleur et les diabètes

Country Status (2)

Country Link
EP (1) EP2242748A1 (fr)
WO (1) WO2009089448A1 (fr)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7141597B2 (en) * 2003-09-12 2006-11-28 Allergan, Inc. Nonsedating α-2 agonists

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2009089448A1 *

Also Published As

Publication number Publication date
WO2009089448A1 (fr) 2009-07-16

Similar Documents

Publication Publication Date Title
US10799492B2 (en) Deuterated analogs of pridopidine useful as dopaminergic stabilizers
CN113906013B (zh) 吡啶氮氧化合物及其制备方法和用途
DE69737980T2 (de) Nitrosierte und nitrosylierte alpha-adrenorezeptoreantagonisten, zubereitungen und deren verwendungen
AU744259B2 (en) Analogs of cocaine
RU2007101653A (ru) Производные 1-азабицикло[3.3.1]нонанов
CN105412092B (zh) 用于降低眼内压的[3-(1-(1h-咪唑-4-基)乙基)-2-甲基苯基]甲醇的酯前药
CN1218045A (zh) 酰胺衍生物或其盐类
JP2006500403A (ja) キノリルプロピルピペリジン誘導体およびその抗菌性物質としての使用
KR20110117706A (ko) Ｓ１ｐ5 수용체의 효능제 및 길항제, 및 이들의 사용 방법
US20200369621A1 (en) Substituted imidazolecarboxylate derivatives and the use thereof
JP2007515447A5 (fr)
RU2004136853A (ru) (s)-4-амино-5-хлор-2-метокси-n-[1-[1-(2-тетрагидрофурилкарбонил)-4- пиперидини лметил]-4-пиперидинил]бензамид, способ его получения, содержащая его фармацевтическая композиция и промежуточное соединение для его получения
UA54385C2 (uk) N-заміщені азагетероциклічні карбонові кислоти та їх ефіри, спосіб їх одержання, фармацевтична композиція та спосіб лікування
JP3839665B2 (ja) 置換２−ベンジルアミノ−２−フェニル−アセトアミド化合物
EP3930722A1 (fr) Traitement avec des modulateurs de p2x3
WO1996031470A1 (fr) Nouveaux composes heterocycliques
AU2017325870B2 (en) Tetrahydroisoquinoline kappa opioid antagonists
JP5571072B2 (ja) アルファアドレナリン介在症状の治療方法
CN1064865A (zh) 4-[(2-苯并噻唑基)甲氨基]-a-[(3，4-二氟苯氧基)甲基]-1-哌啶乙醇
WO2009089448A1 (fr) Composés thérapeutiques disulfure pour traiter la douleur et les diabètes
CN115677507A (zh) 氟比洛芬衍生物及其在药物中的应用
JPH05213957A (ja) 新規なスピロピロリジンイミダゾリン誘導体および新規なアミノピロリジンカルボン酸誘導体並びに該化合物を有効成分とする鎮けい剤
US20100173903A1 (en) Bicyclic amide derivatives for the treatmet of respiratory disorders
WO2018039641A1 (fr) Procédés et composés pour le traitement de troubles d'utilisation d'alcool et de maladies associées
EP2414323B1 (fr) Dérivés d'aminocyclobutane ou d'aminocyclobutène, leur procédé de préparation et leur utilisation comme produits médicaux

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20100810

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA RS

RIN1 Information on inventor provided before grant (corrected)

Inventor name: NGUYEN, PHONG, X.

Inventor name: HEIDELBAUGH, TODD, M.

Inventor name: RUBINO, MARK, P.

Inventor name: AMBRUS, GYORGY, F.

17Q First examination report despatched

Effective date: 20101229

DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20110510